Agreement Details

  • Signed on July 24, 2026
  • Non-exclusive voluntary licensing agreement
  • Royalty-free agreement
  • Covers generic alimatravir supply
  • Targets 129 Low- & Middle-Income Countries (LMICs)
  • LMICs account for the majority of new HIV diagnoses globally

Manufacturing and Supply Terms

  • Aurobindo Pharma is licensed to manufacture and supply generic alimatravir
  • Subject to applicable regulatory approvals and requirements
  • Products will meet internationally recognized standards following regulatory approvals
  • Agreement executed before Phase 3 trial enrollment is completed - a first in HIV prevention

Strategic Purpose

The agreement is intended to enable right scale-up of manufacturing capacity and supply chain preparation in advance of potential regulatory approvals.

Management Commentary

Umesh K, Associate President & Head – Global Access & Licensing stated: "At Aurobindo Pharma, expanding access to high-quality, affordable medicines remains central to our purpose. Our collaboration with MSD reflects our continued commitment to partnering with innovators to accelerate equitable access to potential new therapies. Through this voluntary licensing agreement, we look forward to making alimatravir available across eligible low- and middle-income countries, subject to successful development and regulatory approvals, helping strengthen global efforts towards HIV prevention."

Gregg Szabo, senior vice president, Global HIV Marketing, MSD commented: "We are pleased to be working with Aurobindo and the other manufacturers involved in these voluntary licensing agreements to manufacture generic alimatravir in 129 LMICs, if approved. We hope this early action will help stakeholders across the HIV response begin planning for the scale-up needed to reach people who could benefit from HIV prevention, following the necessary regulatory approvals."

Regulatory Filing

  • Filed with National Stock Exchange of India Limited (Company Code: AUROPHARMA)
  • Filed with BSE Limited (Company Code: 524804)
  • Filed under digital signature of B. Adi Reddy, Company Secretary
  • Filing date: July 24, 2026

Company Background

Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India that develops, manufactures, and commercializes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients in over 150 countries. The company has 31 manufacturing and packaging facilities approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA.

Financial Impact

Financial impact not quantified in the disclosure. The agreement is royalty-free and contingent upon regulatory approvals and successful development of the product.